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ABSTRACT
Respiratory viruses pose a significant risk to population health namely because
the emergence of novel, highly virulent virus strains have the potential to lead to
widespread infection. There is an increasing need for broadly effective antiviral drugs.
Antiviral drugs often enhance specific effects of the host’s natural immune response to
virus infections. Thus, a complete understanding of the host innate immune response to
viruses can offer opportunities to identify possible antiviral drug targets.
It is well known that interferons coordinate a number of antiviral activities in
response to viruses. One effect of type I and type II interferons is the induced production
of a family of proteins known as the IFITM (Interferon-Induced Transmembrane)
proteins. These proteins have been shown to restrict several viruses at the host cell entry
stage including Influenza A Virus, SARS Coronavirus, and West Nile Virus. Recently,
IFITM3 has been identified as an essential factor in host defense against Influenza A
Virus in mice and humans. However, the mechanism by which the IFITM3 protein
restricts virus host cell entry is unclear.
IFITM3 may function both intracellularly and extracellularly to block virus
infection in the human lung. The extracellular milieu contains microscopic vesicles
termed exosomes which derive from multivesicular bodies. Exosomes contain a wide
variety of proteins, and previous studies on these vesicles suggest a role in innate
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immunity. This study aims to determine whether IFITM3 proteins are secreted in the
human lung via exosomes and if so, whether IFITM3-containing exosomes possess
antiviral activity.
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CHAPTER I
INTRODUCTION
The human respiratory tract exposes the lung to the outside world, allowing
foreign particles and pathogens to easily access the lung. Viruses transmitted via the
inhalation of respiratory droplets take up residence in the lung and, in some cases, can
access the blood or lymph system to spread to other tissues in the body. Respiratory
viruses pose a significant risk throughout the world. They are easily transmitted from
person-to-person and can also be transmitted from one mammalian or bird species to
another. One of the greatest problems associated with respiratory viruses is their ability to
undergo antigenic shift or drift. These events occur as a result of mutations that take place
in virus strains over time or if the genomes of two or more virus strains rearrange to form
a new strain. For example, there are several strains of Influenza A Virus. Influenza A
Virus is a segmented RNA virus, so rearrangement of the RNA segments is not
uncommon. It is also possible for the RNA segments from two or more virus strains to
rearrange thereby generating a unique and novel virus strain. Novel virus strains that
emerge following these events are not always predictable and have the potential to spread
throughout unsuspecting populations rapidly. This occurred in 2009 when the H1N1
subtype of Influenza A Virus emerged and subsequently caused a pandemic. Such events
are problematic for humans because, while vaccines against certain respiratory virus
strains do exist (i.e. influenza vaccine”), these vaccines must be altered each year to
1
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account for the emergence of new virus strains. Further, novel virus strains are often
more virulent than those from which they developed. This is because viruses often evolve
to bypass certain host defense mechanisms. With increasing virulence, virus infections
become more difficult to prevent and treat. A main concern is the potential for epidemics,
which occur when the scientific and medical communities are not equipped to manage
the spread of novel virus strains throughout large populations.
The rising number of epidemics caused by respiratory virus infections over the
past several decades has resulted in a growing need for antiviral drugs. Antiviral drugs
typically exploit a step in the virus life cycle. However, antiviral drugs can also be
developed to enhance host defense mechanisms or to prevent viruses from evading host
defense mechanisms. The host innate immune response to respiratory viruses is a
complex series of events, some of which are not entirely understood. A more complete
understanding of the events occurring as part of the host innate immune response to
respiratory viruses in the human lung could create opportunities for future antiviral drug
development.
The recent finding that a particular protein known as IFITM3 is critical for host
defense against influenza virus has heightened interest in the IFITM protein family
among scientific and medical research communities. While the precise mechanism by
which IFITM3 restricts influenza virus infection is not entirely clear, this protein has
been identified as a potential target for antiviral drug development. Also interesting is the
IFITM3 protein’s ability to block virus infection among viruses other than influenza
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virus. The broad antiviral effect of IFITM3 further marks this protein as an important
target for research.
The overarching goal of this study is to determine the antiviral effect of
extracellular IFITM3 in the human lung. More specifically, this study addresses whether
IFITM3 is secreted into extracellular vesicles in the human lung and thereby renders
these vesicles antiviral.

CHAPTER II
BACKGROUND
Interferons orchestrate the innate immune response to virus infection in the
human lung. Type I interferons, in particular, are produced by various cells in the lung
including lymphocytes, macrophages, and lung epithelial cells[1]. Among the family of
type I interferons, two are well-known for their direct antiviral activity: IFNα and IFNβ.
The receptor for IFNα and IFNβ is known as IFNAR[1, 2]. Those cells which display the
IFNAR can bind interferons in the extracellular space and subsequently initiate a
complex intracellular signaling cascade[3]. This signal cascade causes natural killer cells
and macrophages to exert their respective antiviral activities. Among lung epithelial cells,
the signal cascade will involve many factors and ultimately lead to the enhanced
expression of many interferon stimulated genes[4, 5]. There are hundreds of interferon
stimulated genes, each of which plays a specific role in preventing virus replication and
spread.
One subset of interferon stimulated genes is the interferon-induced
transmembrane (IFIT) protein family[6-8]. The IFIT proteins have been implicated in a
wide variety of biological processes such as tumorigenesis, bone remodeling, and virus
restriction[9-11]. Many cell types endogenously express the IFITM genes. However,
because different members of the IFITM family are involved in different cellular
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activities, certain IFITM proteins will only be produced by specific cell types. Further,
there are particular cell types which constitutively produce IFITM rather than simply
produce IFITM upon binding of interferon[12]. Macrophages, for example, constitutively
produce IFITM3, where as tissue specific epithelial cells are more likely to only
upregulate IFITM3 expression in the presence of a virus[13].
This study is particularly interested in the IFITM proteins as antiviral factors.
Several groups have studied these proteins and their ability to restrict virus infection.
IFITM proteins 1,2, and 3 have been shown to have antiviral activity against Influenza A
Virus[11]. In addition to Influenza A Virus, these IFITM proteins have been reported to
restrict West Nile Virus, Dengue Virus, SARS Coronavirus, and HIV-1, among
others[11, 14-19]. IFITM3, in particular, exerts the greatest antiviral effect[11]. A
knockout mouse model demonstrated that IFITM3 is essential for preventing Influenza A
Virus infection in vivo[20]. Further, a study which assessed the IFITM3 alleles of a
population of hospitalized patients infected with H1N1 Influenza Virus during the 2009
epidemic showed that patients with a mutant IFITM3 allele are more susceptible to being
infected with influenza viruses[20]. This mutant IFITM3 allele is generated due to a
variant splice site which causes IFITM3 proteins to lack the first 21 amino acids of the
typically 133 amino acid protein. The mutant IFITM3 protein is far less effective than
wildtype IFITM3 at blocking virus infection[21]. Additionally, the mutant IFITM3
protein is localized to the cellular periphery, unlike wildtype IFITM3 proteins which
localize within endosomal compartments[21]. Although the precise mechanism by which
IFITM3 blocks virus-host cell entry is not entirely understood, previous studies report
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that the first 21 amino acids of IFITM3 are required for its antiviral activity and its
localization to endosomal compartments within the cell[20, 21].
Recent findings regarding IFITM3 provide hints as to how exactly IFITM3
functions mechanistically to block virus infection. Contrary to its name, IFITM3 is not
likely a transmembrane protein, but rather its structure more likely gives the protein an
intracellular membrane topology[22]. The topology of IFITM3 at the plasma membrane
is important to keep in mind when thinking about the mechanism by which the IFITM3
protein restricts virus cell entry. Also notable is the finding that IFITM3 undergoes posttranslational modifications such as palmitoylation and also ubiquitination[22]. Previous
publications suggest both palmitoylation and ubiquitination of the IFITM3 protein
regulate the antiviral effects of IFITM3[13, 22]. The amino acid sequence of IFITM3
contains three cysteines upon which the protein can be palmitoylated. Palmitoylation of
IFITM3 directs this protein to tetraspanin-enriched microdomains at the plasma
membrane[13]. Ubiquitination, on the other hand, can occur on any of the four lysines
present in the amino acid sequence of IFITM3. Ubiquitination of IFITM3 allows this
protein to enter the endocytic network. A recently published finding suggests that the
IFITM proteins, including IFITM3, restrict viral membrane hemifusion[23]. This finding,
when pieced together with our previous knowledge about IFITM3, suggests that IFITM3
is endocytosed and, within the endosome, functions to blocks virus-host cell membrane
fusion and subsequent release of viral RNA into host cell cytoplasm.
IFITM3 is one of many antiviral factors present in the human lung. A complex
network of antiviral proteins, molecules, and signaling pathways function in the human
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lung to block virus replication and damage to the host. These antiviral elements and
pathways must function in harmony to exert the greatest inhibitory effect against
respiratory viruses.
Oftentimes, antiviral factors and signaling pathways facilitate the intercellular
communication that is imperative for eradication of a virus. When the human lung is
under attack by a virus, host cells must have methods to communicate with one another in
order to spread the message that viral replication is occurring. The production and
secretion of interferons and cytokines alert other host cells of the presence of a virus and
activate intracellular signaling pathways which will ultimately lead to the production of
many antiviral proteins[3, 4]. Another form of intercellular communication is thought to
occur via tiny nanovesicles known as exosomes[24-27]. Exosomes originate in the
endocytic pathway of a cell[28]. When an endosome undergoes acidification and
maturation, tiny vesicles may bud inward into the lumen of the endosome, forming a
multivesicular body[29, 30]. There are several possible fates of a multivesicular body.
One possibility is that the multivesicular body goes on to fuse with a lysosome[31]. In
this case, the proteins present in the multivesicular body as well as the membrane
proteins carried by the intraluminal vesicles will be degraded by harsh conditions within
the lysosome. An alternative pathway for the multivesicular body is fusion with the
plasma membrane. In this scenario, the intraluminal vesicles from the multivesicular
body are released into the extracellular space and are subsequently referred to as
exosomes[31]. Exosomes can be distinguished from other extracellular vesicles, such as
apoptotic bodies, by their size, density, and protein composition[32]. Exosomes are
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significantly smaller than other extracellular vesicles, ranging from 40-100nm in
diameter[28, 33]. They are also less dense than other extracellular vesicles, with a density
ranging from 1.1-1.2 g/mL[34-36]. These properties are useful in the isolation of
exosomes from bodily fluids and cell culture supernatants.
Through the purification of exosomes, much has been learned about their
composition. Exosomes display a variety of membrane proteins, carbohydrates, and lipids
on their surface. Proteins in abundance in exosomes are typically those which are
involved with endosomal trafficking[35]. There are a number of proteins high in
concentration in exosomes which effectively serve as exosome markers. TSG101, Alix,
and tetraspanin proteins CD9, CD63, and CD81 are all abundant in exosomes from a
variety of cell types[32, 37]. TSG101 facilitates multivesicular body formation and
therefore exosome formation as well[38]. The Alix protein is involved with several
cellular processes but is secreted into exosomes mainly because of its regulation of
endosomal trafficking and association with ESCRT machinery, specifically, E3 ubiquitin
ligases[39]. The function of tetraspanin glycoproteins CD9, CD63, and CD81 remains
unclear, however, it is known that these cell surface proteins associate with VLA
integrins and HLA-DR, both of which are also abundate in exosomes[32]. A conclusion
that can be drawn from this information is that membrane proteins involved in
multivesicular body formation or endosomal trafficking/sorting are most likely to be
present in exosomes. Additionally, it is notable that a majority of proteins present in
exosomes are ubiquitinated[40]. Thus, proteins that enter the endocytic network via
ubiquitination are more likely to be present in exosomes than non-ubiquitinated proteins.
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Also displayed on the surface of exosomes are lipid rafts, tetraspanin enriched
microdomains, and carbohydrates. Lipid rafts are present in exosomes and have been
implicated in protein sorting into exosomes[41]. Tetraspanin enriched microdomains are
made up of a cluster of tetraspanin glycoproteins and are also present in exosomes[42].
These microdomains exist at the plasma membrane as well. Thus, proteins associated
with these microdomains at the plasma membrane are more likely to end up in exosomes
than proteins localized outside of these concentrated microdomains. Likewise, proteins
associated with certain carbohydrates will be more likely to secrete in exosomes. GM1
gangliosides are present at the plasma membrane and are often secreted in exosomes[43].
Those proteins associated with GM1 gangliosides are more likely to secrete in exosomes
than proteins not associated with these molecules[43].
In addition to the proteins and other molecules that secrete with exosomes,
nucleic acids and retroviruses can be stored in the luminal cavities of exosomes.
Exosomes have been shown to contain viral RNA, retroviruses, and prions [44, 45].
Exosomes are able to be engulfed by phagocytic cells and have been reported to transfer
RNA, retroviruses, and proteins from one cell to another[45-48]. For example, exosomes
have been reported to deliver HIV-1 to host cells via phagocytosis[48]. This finding
would suggest that exosomes are able to promote viral spread and pathogenesis.
Despite the vast amount of information gathered about exosomes, their function
remains disputed among many groups. Exosomes have been implicated in a variety of
cellular processes including intercellular communication, tumorigenesis, inflammation,
and viral pathogenesis[48-51]. Exosomes have also been hypothesized to simply remove
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unwanted proteins, lipids, and other molecules from cells[52]. Many groups that study
exosome properties and function are in agreement that exosomes serve as important
intercellular communication devices[25, 53]. Exosomes are secreted from a variety of
cell types including epithelial cells, macrophages, hematopoietic cells, B cells, T cells,
dendritic cells, platelets, and tumor cells[54-61]. Because exosomes are secreted from a
number of cell types, it is possible that exosomes serve different purposes in different
parts of the body. As of now, exosomes are known to be present in serum, urine, breast
milk, saliva, cerebrospinal fluid, and bronchoalveolar lavage fluid[32].
The detection of exosomes in bronchoalveolar lavage fluid is evidence for
exosome secretion by cells present in the human lung. This finding is of particular
interest to this study. The role that exosomes play in the human lung is not clear.
Exosome secretion in the lung has been shown to induce proinflammatory cytokine
release and subsequent recruitment of inflammatory cells[50, 51, 60, 62, 63]. These data
suggest that exosomes function in concert with other elements of host defense to block
virus infection in the lung.
The primary aim of this study is to determine whether there is a connection
between the antiviral activities of IFITM3 and exosome secretion in the human lung.
Among the constellation of proteins which decorate the exosomal membrane, it is
possible that IFITM3 is present. IFITM3 undergoes ubiquitination and trafficks through
the endocytic network of a cell, so it is plausible that this protein could enter into
multivesicular bodies and secrete into the extracellular space via exosomes[16]. Further,
IFITM3 is reported to be localized within tetraspanin enriched microdomains at the
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plasma membrane[13]. Tetraspanin proteins, CD9, CD81, and CD63, are concentrated in
exosomes and make up the tetraspanin encriched microdomains. These specific
tetraspanins are thought to regulate the sorting of particular proteins into exosomes[64].
Therefore, the localization of IFITM3 to tetraspanin enriched microdomains at the plasma
membrane may be responsible for this protein’s secretion into exosomes.
IFITM3 is suggested to block viral replication at an early step in the viral entry
process[11]. Previous publications suggest IFITM3 blocks virus entry by preventing virus
fusion with the endosomal membrane[23]. In the influenza virus life cycle, following
endocytosis of the virus, acidification of the endosome triggers a conformational change
of the viral hemagglutinin (HA) protein. This conformational change allows for fusion of
the virus membrane with the host endosomal membrane and subsequent release of viral
RNA into the host cell cytoplasm. IFITM3 presumably blocks this fusion event in the
endocytic network of a cell and, thus, IFITM3 is in position to be secreted in exosomes.
If IFITM3 is secreted in exosomes, it may be associated with other proteins including
virus receptors. For example, IFITM3 has previously been shown to associate with lipid
rafts, rich in GM1 gangliosides[23]. GM1 gangliosides are receptors for SV40 and also
contain sialic acid, the receptor for Influenza A Virus. Virus receptors on the surface of
exosomes have been shown to give exosomes the ability to neutralize virus in the
extracellular environment, thereby preventing the viruses from binding and entering host
cells[36]. We hypothesize that IFITM3 interacts with GM1 gangliosides and other virus
receptors to promote their secretion into exosomes. We further hypothesize that the
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recruitment of virus receptors into exosomes by IFITM3 provides exosomes the ability to
neutralize viruses and thereby reduce virus infection levels.

CHAPTER III
RESULTS
Materials and Methods
Plasmid DNAs
Expression plasmids encoding the full-length human IFITM3 protein (pCAGGSHuIFITM3) and N-terminal 21 deletion mutant (pCAGGS-∆21 IFITM3), lacking amino
acids 1-21, were constructed using standard subcloning techniques. DNA encoding either
the full length or mutant IFITM3 gene was cloned into the pCAGGS vector using SacI
and XhoI restriction endonuclease sites. Similarly, the expression plasmid encoding the
Ace2 protein tagged with a C9 tag (pCAGGS-Ace2-C9) was cloned into the pCAGGS
vector using the EcoR1 and Xba1 restriction sites. The pCAGGS-multiple cloning site
vector alone (pCAGGS-MCS) was used in several experiments as a control.
Exosome Sources
Bronchoalveolar Lavage fluid (BALf) samples collected in the Bronchoscopy Laboratory
at Loyola University Medical Center were used for exosome collection. BALf samples
were obtained less than 1 hour following their collection in the Bronchoscopy
Laboratory. BALf samples were kept at 4°C until used for exosome isolation. Exosomes
were isolated from BALf samples within 12 hours of their collection. All cell lines were
cultured in complete medium consisting of Dulbecco modified Eagle medium (DMEM;
Thermo Scientific) supplemented with 10% fetal bovine serum (FBS), 10 mM Na13
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HEPES, 2 mM l-glutamine, penicillin (100 U/ml)-streptomycin (100 μg/ml), 1% sodium
pyruvate , and 1% MEM non-essential amino acids. All cell lines were checked for
mycoplasma infection by PCR.
Isolation of Exosomes
Exosomes were isolated from cell-culture supernatants (HeLa or 293β5 cell lines) or from
human bronchoalveolar lavage fluid by differential centrifugation, as described by Thery
et al[32]. Conditioned medium (CM) was centrifuged (300 x g for 10 minutes) to remove
cells. The pellet was discarded. The clarified CM supernatant was centrifuged (2,000 x g
for 10 minutes) to remove dead cells and cellular debris. Again, the pellet was discarded.
The supernatant was ultracentrifuged (100,000 x g for 70 minutes) to obtain “crude
exosomes”. The crude exosome pellet was washed with serum-free DMEM and
subsequently diluted with serum-free DMEM. The diluted exosomes were then
ultracentrifuged (100,000 x g for 70 minutes) to pellet the “purified exosomes.” The
purified exosome pellet was resuspended in serum-free DMEM. All steps were
performed at 4°C.
Cell Lysate Collection
293β5 and HeLa cells were lysed with a 1% Chaps lysis buffer (10mM Tris HCl, 150mM
NaCl, 0.1% protease inhibitor, 1% Chaps) while rocking on ice for 20 minutes. Crude
cell lysates were then centrifuged (400 x g for 10 minutes at 4°C) to remove cellular
debris. Cells were isolated from bronchoalveolar lavage fluid (BALf) samples by
centrifugation (400 x g, 10 minutes at 4°C). Cells from BALf were then lysed with ice
cold 0.5% Triton X lysis buffer (25mM HEPES, 125 mM NaCl, 0.1% protease inhibitor,
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0.5% Triton X-100) for 10 minutes. Crude cell lysates were centrifuged (400 x g, 10
minutes at 4°C) to remove cellular debris.
Western Blot Analysis
Clarified cell lysate samples and exosome samples were dissolved in sodium dodecyl
sulfate solubilizer (50 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 5% 2mercaptoethanol, and 0.1% bromophenol blue). Samples were then fractionated on a 4%
stacking gel and a 14% resolving gel by SDS-polyacrylamide gel electrophoresis
(PAGE). Samples were then immunoblotted with antibodies reacting with the human
IFITM3 protein (rabbit polyclonal to Fragilis; ABCAM catalog number 74699), the C9
epitope (Mouse monoclonal to rhodopsin; Millipore catalog number MAB5356),
ubiquitin (Mouse monoclonal to Ubiquitin; Santa Cruz Biotechnology Inc catalog
number sc-8017), CD81 (Mouse monoclonal to TAPA-1; BD Pharmingen catalog
number 555746), and CD63 (Mouse monoclonal to CD63; BD Pharmingen catalog
number 556020).
Pseudovirus Infections
Pseudoviruses were generated by transiently transfecting 293T cells (by Calcium
Phosphate transfection) with plasmid DNAs encoding a viral coat protein as well as an
HIV/luciferase core. 48 hours post transfection, conditioned media containing the
pseudovirus was collected. HEPES/NaCl buffer was added to the pseudovirus (final
concentration of 25mM HEPES/125mM NaCl) prior to filtration through a 0.45 micron
seringe filter and storage at -80°C. Pseudoviruses used in this study include
HIV/luciferase or “bald”, SARS S-HIV/luciferase, VSV G-HIV/luciferase, and HA-
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HIV/luciferase pseudovirses. Pseudovirus aliquots were thawed just prior to transduction.
100uL of pseudoviruses were added to 75% confluent 293β5 cells. 48 hours post
transduction, the cell culture supernatant was aspirated and cells were washed twice with
50uL of serum-free media. Following the washes, cells were treated with 1X cell culture
lysis reagent and kept at -80°C for at least 20 minutes. Cells were then thawed to room
temperature. The cell lysate was measured for luminescence using a luminometer.
Luciferase measurements were recorded in relative light units (RLU).
Silver Stain
Exosome samples were dissolved in sodium dodecyl sulfate solubilizer (50 mM TrisHCl, pH 6.8, 10% glycerol, 2% SDS, 5% 2-mercaptoethanol, and 0.1% bromophenol
blue) and were subsequently fractionated using SDS-polyacrylamide gel electrophoresis
(PAGE). Silver staining of the gel was then performed using the Thermo Scientific Pierce
Silver Stain Kit.
AlphaView Software
AlphaView Software (Protein Simple) was used to quantitate band densities on Western
blots. The multiplex band analysis tools were used to outline bands on a Western blot.
Multi-regional background tools were used to select several background regions whose
pixel densities were averaged. The invert function was applied, which reverses the gray
scale assignments so that 0 corresponds to white and 65,535 corresponds to black. The
BC SUM or background corrected sum (background corrected region average x region
area) was recorded for each band.
RESULTS
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IFITM3 protein is secreted into exosomes from cells expressing the IFITM3 gene.
The IFITM3 protein is known to localize in the endosomal compartments of
cells[21]. More specifically, the IFITM3 protein is known to localize to specific regions
of lipid rafts characterized by clusters of tetraspanin proteins[13]. These regions of
tetraspanin clusters are known as tetraspanin webs or tetraspanin enriched microdomains
(TEMs). TEMs traffic through the endocytic network of a cell and are often sorted into
multivesicular bodies[42]. Tetraspanin proteins are abundant in exosomes and are often
used as exosomal markers[32]. One recent report hypothesizes that TEMs are responsible
for protein sorting into exosomes[65]. Specifically, this publication showed data
suggesting that in order for a particular protein to secrete into exosomes, the protein must
associate with TEMs[65].
Because IFITM3 protein localizes to TEMs, we hypothesized that the IFITM3
protein secretes into exosomes. If IFITM3 secretes into exosomes, then we would expect
that when the IFITM3 gene is constitutively expressed among a population of cells in
vitro, the IFITM3 protein can be detected among exosomes isolated from the conditioned
media.
To determine whether IFITM3 exists extracellularly, we evaluated cell-free cell
culture supernatants and bodily fluids for the presence of IFITM3. Endogenous IFITM3
is not easily detected by Western blot among cell culture lysates. To increase intracellular
protein levels of IFITM3, HeLa cells were transfected with plasmid DNA encoding the
human IFITM3 (HuIFITM3) gene (pCAGGS-HuIFITM3). 24 hours post transfection,
cells were lysed with a 1% Chaps lysis buffer. The conditioned media was centrifuged to

18

remove any cells or cellular debris and was subsequently ultracentrifuged to pellet protein
aggregates in the media. The invisible pellet was resuspended in non-reducing SDS
buffer and assessed by Western blot for the presence of IFITM3. Cell lysates were also
evaluated for IFITM3 by western blot. IFITM3 proteins were detected among both the
cell lysates and the cell-free conditioned media samples from HeLa cells overexpressing
the human IFITM3 gene (Fig.1). IFITM3 was not detected among the cell lysates nor was
it detected among the cell-free conditioned media samples from HeLa cells transfected
with the empty vector plasmid. Based on these results, we can conclude that IFITM3
exists extracellularly.
A key caveat to this experiment, and other experiments to be described in this
thesis, is that transient transfection of cells with the IFITM3 gene, and other genes, leads
to levels of intracellular IFITM3 protein production that exceed typical biological levels
of IFITM3 protein production. Because of this, the effects of IFITM3 protein production
observed may be exaggerated effects or could even be effects not taking place at all in the
human body. For these reasons, the results of this experiment and other experiments
requiring transient transfections should be interpreted with caution.
Another key caveat to this experiment and others that require the isolation of
exosomes from cell culture supernatants and biological fluids is that there are
extracellular vesicles aside from exosomes that are roughly the same size and density as
exosomes. Specifically, there is a slight overlap in the size and density of exosomes and
some microvesicles[33]. This means that the differential centrifugation technique used to
isolate exosomes from other extracellular vesicles may not be entirely effective.
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Therefore, while a majority of the extracellular vesicles isolated by differential
centrifugation are most likely exosomes, it is possible that some microvesicles are also
pelleted by the ultracentrifugation steps during preparation of exosome pellets. It is
important to recognize that because microvesicles could be contaminating the exosome
samples, we must be cautious with our interpretations regarding exosome structure and
function.
N-terminal region of IFITM3 protein is not required for secretion into exosomes.
A recent study reported that IFITM3 is essential for host protection against
influenza virus infection. This study showed that mice lacking IFITM3 experience fullblown lung infection when exposed to even low-pathogenicity influenza viruses[20].
Furthermore, the same group identified a number of patients hospitalized with H1N1
(2009) possessing an allelic variant of the IFITM3 allele[20]. The allelic variant results in
the generation of a short IFITM3 protein lacking the N-terminal 21 amino acids. The
IFITM3 deletion mutant was found to lack wildtype IFITM3’s antiviral activity against
influenza virus[20]. We speculated that the inability of the IFITM3 deletion mutant to
block virus infection coincided with an inability of the IFITM3 deletion mutant to secrete
into exosomes. Further supporting this speculation was evidence that the N terminus of
IFITM3 is required for IFITM3 proteins’ localization to endosomal compartments. One
publication showed that the IFITM3 deletion mutant is not localized to the endosome, but
rather is localized to the cellular periphery[21]. Because wildtype IFITM3 is known to
localize to tetraspanin enriched microdomains (TEMs) within endosomal compartments,
we reasoned that the N terminus of the IFITM3 protein may be required for IFITM3
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proteins’ association with TEMs. If this were found to be true, then we would not expect
the IFITM3 deletion mutant to secrete into exosomes, as TEMs are thought to be
responsible for the sorting of TEM-associated proteins into exosomes[65].
We hypothesized that the N terminal 21 amino acids of the IFITM3 protein are
required for the protein’s ability to secrete into exosomes. If the N terminus of IFITM3 is
required for IFITM3’s secretion into exosomes, then we would not expect to detect the
IFITM3 deletion mutant among exosomes from cells expressing the gene encoding the
IFITM3 deletion mutant.
In order to determine whether the IFITM3 deletion mutant, referred to as ∆21
IFITM3, secretes into exosomes, human embryonic kidney cells (293β5 cells) were
transfected with plasmid DNA encoding ∆21 IFITM3 (pCAGGS-∆21 IFITM3). 24 hours
post transfection, the conditioned media was collected and centrifuged to remove cells
and cellular debris. The media was then ultracentrifuged as previously described to pellet
exosomes. Exosome samples were resuspended in non-reducing SDS lysis buffer and
evaluated via Western blot for the presence of the ∆21 IFITM3 protein. Cell lysates were
also obtained and evaluated by Western blot to verify the production of intracellular ∆21
IFITM3 protein. As expected, the wildtype IFITM3 protein was detected among
exosomes from cells expressing the IFITM3 gene. Unexpectedly, the results of this
experiment suggest that the ∆21 IFITM3 protein is also able to secrete into exosomes, as
the ∆21 IFITM3 protein was detected among the exosomes from cells transfected with
∆21 IFITM3 cDNA (Fig. 2).
A majority of extracellular IFITM3 proteins exist in exosomes.
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Following our previous finding suggesting the IFITM3 protein secretes into
exosomes, we set out to strengthen our data supporting the idea that extracellular IFITM3
proteins pelleted from conditioned media samples are truly present in exosomes.
Exosomes are known to dissolve upon treatment with a variety of detergents including
some non-ionic detergents like NP40[66]. Thus, we expect exosomes to lyse upon
treatment with 0.5% NP40. By treating cell culture supernatants or biological fluids with
a non ionic detergent such as NP40, exosomes will be lysed and the proteins and
materials associated with or carried by exosomes will not be collected using the
differential centrifugation technique described in the methods section of this thesis.
We hypothesized that the extracellular IFITM3 we previously detected among cell
culture supernatants is present in exosomes. If extracellular IFITM3 proteins are present
in exosomes, then we expect to not pellet IFITM3 among conditioned media samples
treated with NP40, as NP40 will lyse the exosomes.
To determine whether the extracellular IFITM3 proteins detected in previous
experiments by Western blot are present in exosomes, human embryonic kidney cells
(293β5) were transfected with cDNA encoding IFITM3 (pCAGGS-HuIFITM3). 24 hours
post transfection, the conditioned media was collected and centrifuged to remove cells
and cellular debris. The cells were lysed using 1% Chaps lysis buffer and subsequently
centrifuged to purify the cytoplasmic portion of the cells. These samples were set aside
for Western blot. The conditioned media samples either received treatment with 0.5%
NP40 or serum-free media. The media samples were then ultracentrifuged to pellet
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exosomes. At this step, we anticipate that those media samples treated with the NP40 will
no longer contain intact exosomes. Therefore, the exosomes and their contents will not
pellet during ultracentrifugation. Following ultracentrifugation, the pelleted material was
resuspended in non-reducing SDS buffer and evaluated by Western blot for the presence
of IFITM3 proteins. We expected IFITM3 to be detected only among the media samples
that did not receive NP40 treatment, because exosomes containing IFITM3 proteins will
remain intact in these samples and therefore be pelleted during ultracentrifugation. In
contrast, we expected to detect no IFITM3 among the media samples treated with NP40,
as exosomes in these samples will be destroyed and IFITM3 proteins will not be pelleted
during ultracentrifugation. Our results confirmed our hypothesis that extracellular
IFITM3 proteins are present in NP40 sensitive vesicles (Fig 3). Monomeric IFITM3
proteins were not detected among the media samples treated with NP40 lysis buffer,
meaning that extracellular monomeric IFITM3 proteins are present in exosomes. We did,
however, detect low levels of higher molecular weight IFITM3 proteins among the media
samples treated with NP40. These bands were also seen among the media samples that
did not receive treatment with NP40 and at greater levels than among samples treated
with NP40. Thus, we conclude that a portion of extracellular high molecular weight
IFITM3 proteins is present in exosomes. The higher molecular weight forms of IFITM3
that we do detect among the media samples treated with NP40 are possibly oligomeric
forms of IFITM3 proteins which are part of a larger protein aggregate. However, lipid
rafts and some tetraspanin enriched microdomains are resistant to treatment with non
ionic detergents such as NP40[67]. Thus, another possibility is that the higher molecular
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forms of IFITM3 detected among the media samples treated with NP40 are actually
IFITM3 proteins that were not disassociated from tetraspanin enriched microdomains
during treatment with NP40. Regardless of the presence of the higher molecular weight
forms of IFITM3 detected by Western blot, the results of this experiment suggest that a
majority if not all of the extracellular IFITM3 proteins are present in exosomes.
IFITM3 proteins are secreted into exosomes in the human lung.
Type I and type II interferons are released in the human lung in response to virus
infection[2, 4, 5, 68, 69]. IFITM3 is one of the hundreds of interferon effectors that
comprise the immediate host response to virus infection[68, 70]. The IFITM3 protein has
been shown to block cytosolic entry of multiple respiratory viruses including Influenza A
Virus and SARS Coronavirus[11, 18]. Additionally, individuals possessing the allelic
variant of IFITM3 are less protected from influenza viruses[20]. Based on this evidence,
we know that IFITM3 exerts antiviral activities in cells present in the human lung.
Exosomes are secreted from a variety of cell types and can be isolated from a
number of bodily fluids[32]. One fluid from which exosomes can be isolated is
bronchoalveolar lavage fluid, collected from the human lung[50, 63, 71]. By isolating
exosomes from bronchoalveolar lavage fluid samples, it is possible to evaluate human
lung derived exosomes for proteins of interest.
With this knowledge and our findings that suggest IFITM3 is secreted into
exosomes under cell culture conditions, we hypothesized that IFITM3 proteins are
secreted into exosomes in the human lung. If IFITM3 proteins are secreted into exosomes
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in the human lung, then we expect to detect IFITM3 among exosomes isolated from
bronchoalveolar lavage fluid samples across a population of patients.
To determine whether IFITM3 protein is secreted into exosomes in the human
lung, we obtained fresh bronchoalveolar lavage fluid (BALf) samples from patients
undergoing the bronchoscopy procedure within the Pulmonology Department at Loyola
University Medical Center. BALf samples were centrifuged to isolate cells present in the
fluid. The cells were lysed with 1% Chaps lysis buffer. Cell-free BALf samples were
treated the same as the conditioned media samples in the previous in vitro assay. Both the
cell lysates and BALf samples were evaluated for the presence of IFITM3 protein.
IFITM3 proteins were detected among both the cell lysates and the cell-free BALf
samples of several patients (Fig. 4). Thus, these data suggest that IFITM3 proteins are
secreted into the extracellular space by cells present in the human lung.
Exosomal IFITM3 proteins in the human lung are ubiquitinated.
We observed over the course of several in vitro experiments that intracellular
IFITM3 proteins typically exists as either monomeric or dimeric IFITM3, whereas
IFITM3 proteins in exosomes are detected in their monomeric form as well as at various
higher molecular weights. Based on the molecular weights of the IFITM3 detected in
exosmoes, we hypothesized that oligomeric forms of the IFITM3 protein were
responsible for these bands. However, the higher molecular weight forms of exosomal
IFITM3 observed among bronchoalveolar lavage fluid (BALf) samples did not generate
the characteristic ladder observed among exosome samples collected from cell culture
supernatants. Thus, we hypothesized that the population of high molecular weight
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exosomal IFITM3 observed in BALf samples was not oligomeric, but rather, posttranslationally modified forms of IFITM3.
Previous studies have demonstrated that IFITM3 proteins undergo post
translational modifications including palmitoylation and ubiquitination[22]. It has also
been previously reported that a vast majority of proteins present in exosomes are
ubiquitinated[40].
We hypothesized that the higher molecular forms of IFITM3 proteins observed in
human lung derived exosomes are ubiquitinated forms of IFITM3. If IFITM3 proteins
present in human lung derived exosomes are ubiquitinated, then the ubiquitin and
IFITM3 profiles among exosomes isolated from BALf samples should demonstrate some
level of similarity.
In order to determine whether IFITM3 proteins in exosomes are ubiquitinated, we
compared IFITM3 protein banding patterns with ubiquitin band patterns using Western
blot technique. This question was first addressed by studying IFITM3 proteins in
exosomes from BALf samples. Exosomes were purified from BALf samples as
previously described and were subsequently evaluated by Western blot for the presence
of IFITM3 protein. The samples were separately evaluated for the presence of ubiquitin.
The IFITM3 protein banding patterns and ubiquitination patterns were compared side by
side. In one interesting case, the IFITM3 and ubiquitination protein patterns appeared
nearly identical(Fig. 5A). This result suggests IFITM3 proteins in exosomes are indeed
ubiquitinated. Several patients’ BALf samples were evaluated in this way. In some cases,
IFITM3 proteins in exosomes from the human lung were very clearly ubiquitinated(Fig.
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5B). In other cases, however, it was difficult to determine whether IFITM3 proteins in
exosomes were ubiquitinated (Fig. 5C). This was because the banding pattern of ubiquitin
appeared more diffuse, suggesting an abundance of ubiquitinated proteins among the
exosomes. From the sum of these data, we conclude that ubiquitinated IFITM3 proteins
are secreted into exosomes. We cannot conclude, however, that ubiquitinated IFITM3
protein accounts for all higher molecular weight forms of extracellular IFITM3.
IFITM3 protein induces exosome secretion.
Previously published reports have shown that lung inflammation is associated
with exosome secretion. Specifically, the more inflamed the human lung is, the more
exosomes are secreted into the human lung[50]. For example, patients with sarcoidosis, a
lung condition characterized by granuloma formation and the production of interferon
gamma, were shown to have more exosomes present in bronchoalveolar lavage fluid
(BALf) samples compared to healthy persons[50]. Additionally, cigarette smokers were
shown to have higher levels of exosomes present in their BALf samples compared with
non-smokers[50].
This knowledge, in combination with our observation that a vast majority of
exosomes isolated from BALf samples for this study contained IFITM3, led us to
hypothesize that IFITM3 induces exosome secretion. If IFITM3 induces exosome
secretion, then we would expect to detect more exosomes (as measured by exosomal
markers) when the IFITM3 gene is overexpressed.
To determine whether the IFITM3 protein induces exosome secretion, human
embryonic kidney (293β5) cells were transiently transfected with plasmid DNA encoding
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the human IFITM3 gene (pCAGGS-HuIFITM3) or with the empty pCAGGS vector
(pCAGGS-MCS). 24 hours post transfection, the conditioned media was collected and
centrifuged to remove cells and cellular debris. The media was then ultracentrifuged as
previously described to pellet exosomes. The 293β5 cells were lysed with 1% Chaps lysis
buffer. The clarified cell lysates and exosome samples were evaluated by Western
blotting. First, the IFITM3 protein was detected in order to verify the intracellular
production of the IFITM3 protein and its secretion into exosomes from cells transfected
with plasmid DNA encoding IFITM3 (Fig. 6). Next, exosome secretion was assessed by
detecting well-known exosome markers, CD63 and CD81 by Western blot (Fig.6). In
order to quantitate exosome secretion, AlphaView software was used to measure the
Western blot band densities of CD63 and CD81 among cell lysates and exosomes. Band
densities were corrected for background levels and were also corrected to account for the
fraction of cell lysate or exosome sample fractionated by SDS-PAGE. The final corrected
values were recorded as BC SUM (background corrected sum) and BC SUM
ADJUSTED (background corrected sum corrected to represent entire cell lysate or
exosome preparation) (Fig. 7). Results of the AlphaView analysis demonstrated an
increased proportion of CD63 and CD81 protein secretion among cells transfected with
plasmid DNA encoding HuIFITM3 compared with cells transfected with the vector
control (Fig. 7). Roughly twice as much CD63 and CD81 protein was secreted from cells
transfected with plasmid DNA encoding HuIFITM3 than cells transfected with the vector
control (Fig. 7). This result suggests that HuIFITM3 protein induces exosome secretion.
Exosomes’ antiviral activity against Influenza A Virus is not likely mediated by IFITM3.
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A previously published report suggests exosomes released from tracheobronchial
epithelial cells possess antiviral activity against Influenza A Virus[36]. This publication
showed that mucin proteins (MUC1, MUC4, and MUC16) present on the surface of
exosomes secreted from human tracheobronchial epithelial cells in cell culture are
associated with sialic acids[36]. Further, this study showed that the exosomes released
from human tracheobronchial epithelial cells are able to bind influenza virus via the
interaction between sialic acid displayed on the exosomal surface with viral
hemagglutinin proteins[36]. Exosomes that bind the influenza virus are able to neutralize
the influenza virus and thereby inhibit virus infection[36].
Our previous findings suggest IFITM3 proteins induce exosome secretion. Thus,
we hypothesized that IFITM3 enhances and mediates the antiviral activity of exosomes.
If IFITM3 mediates exosomes’ antiviral activity, then we expect to see infection levels
decrease when exosomes from IFITM3-expressing cells are mixed with influenza
pseudoviruses prior to infection.
To determine whether IFITM3 protein mediates exosomes’ ability to neutralize
influenza virus, human embryonic kidney (293β5) cells were transfected with plasmid
DNA encoding the IFITM3 gene (pCAGGS-HuIFITM3). 24 hours post transfection,
exosomes were purified from the conditioned media as previously described. The
exosomes were then mixed with Influenza A pseudoviruses containing hemagglutinin
(HA) coat proteins and HIV/luciferase cores. The exosome/pseudovirus mixture was
incubated at room temperature for one hour before being applied to human emybronic
kidney (293β5) target cells. 48 hours post transduction with the pseudovirus, luciferase
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values were read. Results of the luciferase reading suggest exosomes from cells
overexpressing the IFITM3 gene are not antiviral. However, exosomes collected from
cells not overexpressing the IFITM3 gene possessed antiviral activity against influenza
pseudovirus (Fig. 8A). To verify the difference in antiviral activity among the two
subsets of exosomes was dependent upon the level of exosomes mixed with pseudovirus,
a silver stain was performed on both samples. The silver stain results showed no
significant difference in the level of protein among the two exosome samples (Fig. 8B).
This result suggests the level of exosomes collected from cells overexpressing the
IFITM3 gene is similar to the level of exosomes collected from cells not overexpressing
IFITM3. The presence of IFITM3 protein among exosomes collected from cells
overexpressing the IFITM3 gene was also verified by Western blot (Fig. 8C). Based on
the sum of these results, we conclude IFITM3 protein does not mediate exosomes’ ability
to neutralize influenza virus.
IFITM3 induces secretion of receptor for SARS Coronavirus into exosomes.
The IFITM3 protein is known to localize to tetraspanin enriched microdomains
(TEMs) specifically in endosomal compartments of the cell[13, 21]. Tetraspanin enriched
microdomains contain a wide variety of proteins suggesting IFITM3 is in a position to
interact with other proteins.
We hypothesized that IFITM3 interacts with specific virus receptors and induces
their secretion into exosomes. If IFITM3 induces the secretion of virus receptors into
exosomes, then we expect that a greater level of virus receptor is secreted into exosomes
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from cells constitutively expressing the IFITM3 gene compared with cells not
constitutively expressing the IFITM3.
IFITM3 protein has been shown to block SARS Coronavirus infection[18].
Therefore, we set out to test our hypothesis by determining whether IFITM3 induces the
secretion of the receptor for SARS Coronavirus (Ace2) into exosomes. HeLa cells were
transfected with either plasmid DNA encoding the Ace2 gene (pCAGGS-Ace2-C9),
equal masses of plasmid DNA encoding the Ace2 and IFITM3 genes (pCAGGS-Ace2C9 and pCAGGS-HuIFITM3), or an empty vector (pCAGGS-MCS). 24 hours post
transfection, exosomes were purified from the conditioned media as previously described
and were evaluated by Western blot for the presence of IFITM3 and Ace2. Cell lysates
were also evaluated in this way. Our results suggest that when the IFITM3 gene is
expressed in HeLa cells, a greater level of Ace2 is secreted into exosomes compared to
cells not expressing the IFITM3 gene(Fig. 9). These data suggest IFITM3 proteins
promote the secretion of Ace2 receptors into exosomes.
Exosomes secreted from cells expressing the IFITM3 gene block SARS Coronavirus
infection.
Exosomes displaying the receptor for influenza virus (sialic acid) have previously
been shown to neutralize influenza virus [36]. Our previous experiment suggested that
the receptor for SARS Coronavirus (Ace2) can be secreted in exosomes. Therefore, we
hypothesized Ace2-containing exosomes can bind and neutralize SARS Coronavirus. Our
previous data suggest the IFITM3 protein induces Ace2 secretion into exosomes. If
exosomes secreted from cells overexpressing the IFITM3 gene are antiviral against
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SARS Coronavirus, then this antiviral effect would be considered to be mediated by
IFITM3.
To determine whether IFITM3 protein affects exosomes’ ability to block SARS
Coronavirus infection, human embryonic kidney cells were transfected with plasmid
DNA encoding the IFITM3 gene (pCAGGS-IFITM3). Exosomes were isolated from the
conditioned media as previously described. Exosomes were then mixed with
pseudoviruses containing an HIV-luciferase core and a SARS S protein coat. The
exosome/pseudovirus mixture was incubated at room temperature for one hour before
being applied to Ace2-expressing human emybronic kidney (293β5) target cells. 48 hours
post transduction with the pseudovirus, luciferase values were read. Among cells treated
with the mixture containing SARS S pseudovirus and exosomes from IFITM3-expressing
cells, the luciferase data showed lower relative light units than cells treated with the
SARS pseudovirus alone (Fig. 10). These results suggest exosomes possess IFITM3mediated antiviral activity against SARS Coronavirus. Based on these data, it is possible
that exosomes are broadly antiviral.

CHAPTER IV
DISCUSSION
This study demonstrates that when IFITM3 cDNA is expressed in various cell
types, the IFITM3 protein is secreted into exosomes. IFITM3 gene expression is
constitutive in the presence of type I interferons[7, 8]. Thus, based on our results, we can
infer that IFITM3 protein secretion into exosomes is induced by type I interferons. One
control that would be useful in this experiment is one which could verify that
overexpression of any gene does not lead to the secretion of its protein product into
exosomes.
Although it is well known that the IFITM3 deletion mutant (∆21 IFITM3) can
undergo ubiquitination, we hypothesized that (∆21 IFITM3 will not be secreted into
exosomes. This is because ∆21 IFITM3 proteins localize to the cellular periphery[21].
This is in contrast to wildtype IFITM3 proteins, which localize to endosomal
compartments. Exosomes originate in the endocytic network of a cell[29, 52]. Thus, we
inferred that if the mutant IFITM3 is not localized to the endosome, it will not likely
secrete into exosomes. Surprisingly, our results show that ∆21 IFITM3 proteins are able
to secrete into exosomes.
One interesting observation made during our evaluation of the data comparing the
abilities of wildtype IFITM3 and the IFITM3 deletion mutant to secrete into exosomes is
that exosomal IFITM3 is detected at molecular weights much higher than that which is
32
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predicted for monomeric IFITM3 (15kD). These higher molecular weight forms of
IFITM3 were observed over the course of many repeated experiments and were always
detected as a characteristic ladder. Based on the molecular weights of these IFITM3
bands (~30 kD, ~45 kD, ~60 kD, etc), which seemed to increase by approximately the
size of monomeric IFITM3 (15 kD), we propose that this population of higher molecular
weight IFITM3 protein is representative of IFITM3 oligomers.
There is one key caveat to the experiments involving transient transfection of cells
with plasmid DNA encoding the IFITM3 and ∆21 IFITM3 genes, among other genes.
Transient transfection conditions create a state of gene overexpression within cells that is
not biologically natural. Overexpression of genes leads to heightened protein production.
When certain protein levels rise above biologically normal levels, due to transient
transfections, the proteins can have unnatural effects. For example, the ∆21 IFITM3
mutant is known to lack wildtype IFITM3’s ability to block influenza virus infection[20].
However, ∆21 IFITM3 proteins appear to restrict influenza virus infection when
produced at high levels within cells due to transient transfections with a significant mass
of DNA encoding the gene for the deletion mutant. It is possible that when ∆21 IFITM3
proteins are produced in excessive amounts in the cell (due to transient transfection
conditions), the ∆21 IFITM3 proteins are able to function similarly to wildtype IFITM3.
This thought is based on the current data which shows that ∆21 IFITM3 proteins are able
to restrict virus entry only when greatly overproduced within cells. Thus, it is important
to keep in mind that the effects of overexpression of the IFITM3 gene in many of the
experiments described in this document may be exaggerated compared to the normal
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effects of IFITM3 in the human lung or in untransfected cells. Additionally, it is possible
that transient transfections increase not only intracellular protein levels but also increase
exosomal protein levels. Thus, it is possible that IFITM3 deletion mutant is only secreted
into exosomes under transient transfection conditions and that this mutant IFITM3 is not
normally secreted into exosomes in the human lung. One way to address this issue would
be to titrate the mass of plasmid DNA transfected into cells and observe how the effects
of gene expression vary as the amount of DNA transfected into cells is decreased to a
point of no effect. One future direction would be to repeat the experiments in this thesis
that require transient transfections and titrate the plasmid DNA used in each experiment,
for example, by starting with a maximum level of DNA and titrating the DNA by 1:2
dilutions until there are no longer any effects observed. Another possible way to address
the issue of IFITM3 gene overexpression would be to use type I interferon treatment to
induce the intracellular production of the IFITM3 protein. This method of inducing
IFITM3 gene expression would be more comparable to the induction of IFITM3 gene
expression in the human lung. It would be very important in this case to verify that the
interferon sample used to induce IFITM3 gene expression does not contain any other
materials that could potentially alter the outcome of the experiment. It would also be
difficult to verify that effects of interferon treatment are due to IFITM3 and not due to
one of the other hundreds of interferon effectors in the cell. Nevertheless, experiments
using interferon treatment in place of transient transfections of IFITM3 cDNA would still
be a good comparison for experiments requiring titrated DNA transfections.
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We detected the IFITM3 protein among exosomes isolated from a collection of
BALf samples. This finding suggests that cells present in the human lung secrete
exosomes containing IFITM3 protein. The protein composition of exosomes is known to
vary depending on the origin of the cell from which the exosomes were secreted[72].
This is likely because exosomes participate in different activities depending on the cell
types from which they originate as well as their location in the human body. Therefore, it
is plausible that IFITM3 protein is secreted into exosomes specifically in the human lung
in order to facilitate exosomes in lung-specific biologic activities. Exosomes have been
suggested to play a role in the innate immune response to pathogens in the lung[49-51,
60, 73]. Not only have exosomes been implicated in the recruitment of proinflammatory
cells to the site of infection, exosomes have also been implicated in antiviral activities[36,
50, 60, 73]. Therefore, IFITM3 protein may facilitate human lung-derived exosomes’
ability to defend the host against respiratory viruses.
One key issue we encountered while isolating exosomes by differential
centrifugation is that the efficacy of this method relies on the difference in size and
density between exosomes and other extracellular vesicles. This has the potential to be
problematic because there is an overlap in the ranges of size/density among exosomes
and other tiny microvesicles released from cells in response to a particular signal[33].
Specifically, the diameter of exosomes ranges from approximately 30-100nm and the
density of exosomes ranges from 1.1-1.2 g/mL[32]. Microvesicles can range in size from
approximately 75 nm-1 μm and can have densities in the same range as exosomes[33,
74]. Thus, it is important to recognize that because differential centrifugation is the
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method used to isolate exosomes among all of the experiments in this thesis, there are
boundaries to the interpretations we can make regarding exosome structure and function.
Regardless, these experiments are still valid and worthwhile. Differential centrifugation is
a key technique to isolate exosomes and its efficiency and accuracy has been
demonstrated in many published works[32].
One issue encountered with experiments that require the collection of
bronchoalveolar lavage fluid (BALf) samples is the difficulty with normalizing the data.
There are many variables related to the collection of BALf samples such as the amount of
saline used to collect the sample, location of the lung in which the sample is collected,
and the technique of the person collecting the fluid. These variables affect the types of
cells and other extracellular materials present in the BALf sample. Thus, the amount of
protein, cells, and exosomes present in a BALf sample can vary drastically from person
to person. It would be useful to have a method to calculate the number of exosomes
collected in each BALf sample obtained. One way that this could be done is by flow
cytometry. Flow cytometry can count the number of exosomes and can also identify the
abundance of certain exosomal markers and proteins present on the surface of exosomes.
Electron microscopy could also be used to verify the presence of exosomes in BALf
samples and count the number of exosomes in a given volume of BALf. These methods
can provide a way of normalizing the Western blot evaluation of exosomes collected
from BALf samples. Further, these methods would be more accurate in determining the
total amount of exosomes in BALf samples than western blotting and silver stain
techniques that were used in the experiments described in this thesis. With a more

37

accurate understanding of the levels of exosomes among the BALf samples, trends in
exosomal protein content or IFITM3 content, in particular, could be sought out among
patients with the same clinical conditions. Also, by directly evaluating the amount of
exosomal IFITM3 protein present in BALf samples, our conclusions regarding the
secretion of IFITM3 and the potential effects of exosomal IFITM3 on exosome structure
and function will be strengthened and more reliable.
We also show that IFITM3 proteins present exosomes are ubiquitinated. IFITM3
proteins in exosomes isolated from both cell culture supernatants and BALf samples are
detected at various molecular weights ranging from 35-150 kD. This contrasts with the
observation that intracellular IFITM3 proteins predominantly exist in its monomeric form
(between 20-26 kD). Based on our comparison of IFITM3 and ubiquitin banding patterns
among BALf samples, it appears that IFITM3 proteins are ubiquitinated. It also appears,
in some cases, that IFITM3 proteins comprise a majority of the ubiquitinated proteins in
exosomes in the human lung. It is well known that exosomes contain ubiquitinated
proteins[40]. Thus, these data suggest that ubiquitination of IFITM3 strongly promotes
IFITM3 protein secretion into exosomes.
Our results suggest that the IFITM3 protein induces exosome secretion. This is
based on the repeated observation that roughly 1.8 times more CD81 and CD63 protein is
secreted from cells transfected with plasmid DNA encoding HuIFITM3 compared with
cells transfected with an empty vector control. CD81 and CD63 are tetraspanin proteins
abundant in exosomes[32, 75]. Thus, the secretion of CD81 and CD63 proteins directly
correlates with exosome secretion. The IFITM3 protein is known to localize to
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tetraspanin enriched microdomains[13]. The ability of the IFITM3 protein to localize to
tetraspanin enriched microdomains and induce secretion of exosomes from cells suggests
IFITM3 involvement with and promotion of exosome activities.
Previous studies demonstrate that exosomes are able to neutralize Influenza A
Virus due to the presence of sialic acids on the surface of exosomes which can then bind
the virus[36]. IFITM3 proteins present at the plasma membrane localize to regions
enriched with sialic acids[42, 76]. Therefore, we hypothesized that IFITM3 protein
promotes the sorting of sialic acids into exosomes and consequently mediates the ability
of exosomes to neutralize Influenza A Virus. Unexpectedly, we found that exosomes
from cells transiently transfected with IFITM3 cDNA are not antiviral against Influenza
A Virus, while exosomes from cells not overexpressing the IFITM3 gene are antiviral
against Influenza A Virus. We conclude from these data that the IFITM3 protein may be
excluding a particular factor that is required for exosomes to bind Influenza A Virus. A
follow up experiment that will verify our conclusion that IFITM3 proteins prevent
exosomes from neutralizing Influenza A Virus will be to test whether lower levels of
intracellular IFITM3 production correlate with higher levels of exosome-mediated virus
restriction. Another valuable follow up experiment would be to use Western blotting
methods to assess the sialic acid content of exosomes from cells expressing the IFITM3
gene compared to cells transfected with the vector control. Whether IFITM3 affects the
secretion of mucin proteins and other proteins displaying sialic acids into exosomes
would be interesting to determine and could potentially offer an explanation as to why
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IFITM3 appears to prevent exosomes from exerting their antiviral activity against
influenza viruses.
Despite the results that suggest IFITM3 proteins do not mediate exosomes’ antiInfluenzaviral activity, we hypothesized that IFITM3 proteins may promote exosomes’
ability to restrict other respiratory viruses. Evidence supporting this hypothesis included
our finding that IFITM3 promotes the secretion of the receptor for SARS Coronavirus,
Ace2, into exosomes. Interestingly, exosomes from cells transiently transfected with
IFITM3 cDNA were found to reduce SARS S Pseudovirus infection levels. We propose a
model in which the IFITM3 protein recruits the Ace2 receptor into exosomes which,
upon release into the extracellular space, can then bind SARS S Pseudovirus and thereby
reduce virus infection levels (Fig. 11). Obviously, this proposed model is not supported
by the data suggesting IFITM3 does not mediate exosomes’ antiviral activity against
influenza viruses. We acknowledge this and explain this result by proposing a model in
which IFITM3 only mediates exosomes’ antiviral activity against viruses using receptors
whose secretion into exosomes is induced by the IFITM3 protein. Specifically, we
hypothesize that IFITM3 induces the secretion of only certain virus receptors into
exosomes. IFITM3 is known to localize to tetraspanin enriched microdomains (TEMs).
TEMs are known to secrete into exosomes. It is possible that specific virus receptors
localize to TEMs. We hypothesize that IFITM3, through its association with TEMs, has
the ability to drag specific virus receptors into exosomes. This proposed mechanism of
the virus receptor secretion into exosomes suggests that IFITM3 would only mediate
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exosomes’ antiviral activity against those viruses requiring the receptors whose secretion
into exosomes is IFITM3-dependent.
There are several follow up experiments that could potentially further support this
model. In order to verify the presence of Ace2 among the antiviral exosomes,
fractionation of the exosome samples by SDS-PAGE and subsequent detection of the
Ace2 protein by Western blotting could be performed. Additionally, a good control to
add to this experiment would be to add soluble Ace2 to the exosome/pseudovirus
mixture. In this case, we would expect the soluble Ace2 to compete with the exosomes
for pseudovirus binding and the SARS S Pseudovirus infection levels to rise.
Furthermore, it would be valuable to quantitate the number of exosomes/cell or
exosomes/virus particle required to block virus infection. Quantitation of the level of
exosomes used in the infectivity assays could be made possible by use of flow cytometric
analysis of exosomes. Electron microscopy could also be used to determine the number
of exosomes added to cells in the infectivity assays. With this knowledge, conclusions
regarding the potency of antiviral exosomes could be strengthened. Further, the
composition of antiviral exosomes could be assessed by flow cytometric methods which
would be interesting to explore.
An important caveat to the infectivity assays which test the antiviral abilities of
exosomes is that the mechanism of exosomes’ antiviral activity remains a mystery and is
open to multiple interpretations. One possible interpretation of the mechanism by which
exosomes are antiviral is that which was previously described and modeled in Figure 9.
Another possible mechanism by which exosomes are antiviral is that they block virus
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entry in the multivesicular body. Viruses are known to traffic into multivesicular bodies,
where intraluminal vesicles (referred to as exosomes once released into the extracellular
space) could potentially bind and fuse with the viruses, thereby preventing the virus from
releasing its contents into the cytosol. This event would prevent virus replication from
occurring. Another possibility is that exosomes, rather than be involved with the innate
immune response to virus infection, could exert their antiviral activites as part of the
adaptive immune response. Major histocompatability complexes (MHC) Class I which
display viral antigens, are abundant in exosomes. Exosomes displaying virus antigens via
MHC Class I molecules are able to be phagocytosed by dendritic cells, which then go on
to display the virus antigens on their surface and activate natural killer cells and cytotoxic
T cells. Thus, it is possible that exosomes are antiviral via this mechanism. One future
direction related to this possible model is to determine whether IFITM3 induces the
secretion of MHC Class I molecules into exosomes. MHC Class I molecules have been
reported to associate with specific tetraspanin proteins[77]. IFITM3 is also known to
associate with tetraspanin proteins. If IFITM3 were shown to induce the secretion of
MHC Class I molecules via its association with tetraspanin enriched microdomains, then
this could be one of several mechanisms by which IFITM3 mediates exosomes’ antiviral
activity. Additionally, this finding would be the first evidence of IFITM3 protein
involvement with the adaptive immune response to virus infection.
In conclusion, our results suggest that IFITM3 protein mediates virus-specific
antiviral activity of exosomes. This finding provides new insight into the antiviral activity
of exosomes in the human lung.

APPENDIX A:
FIGURES
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FIGURE 1:
Intracellular and Extracellular Human IFITM3 Protein Levels in Cell Culture
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Figure 1. Intracellular and Extracellular Human IFITM3 Protein Levels in Cell
Culture. HeLa cells were transfected with pCAGGS-HuIFITM3 (HuIFITM3), pCAGGSMCS (Vector). At 24 hours post transfection, exosomes were purified from cell culture
supernatants and cells were lysed with 1% Chaps lysis buffer. 1/50 of clarified cell
lysates and ½ of purified exosome sample were fractionated on a 4% stacking and 14%
resolving gel by SDS-PAGE. Human IFITM3 (HuIFITM3) proteins were detected by
Western blotting.
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FIGURE 2:
Effect of ∆21 IFITM3 cDNA Expression on Intracellular and Extracellular ∆21 IFITM3
Levels in Cell Culture

[46]

Figure 2. Effect of ∆21 IFITM3 cDNA Expression on Intracellular and Extracellular
∆21 IFITM3 levels in Cell Culture. 293β5 cells were transiently transfected with either
pCAGGS-HuIFITM3 (hIFITM3), pCAGGS-∆21 IFITM3 (∆21 IFITM3), or pCAGGSMCS (Vector). 24 hours post-transfection, the conditioned media samples were collected.
Exosomes were purified from conditioned media by ultracentrifugation. Cells were lysed
with 1% Chaps lysis buffer. ¼ of the exosome samples and 1/160 of cell lysates were
fractionated on a 4% stacking and 14% resolving gel by SDS-PAGE. Wildtype and
deletion mutant IFITM3 proteins were detected by Western blotting. Positions of
molecular mass standards (in kilodaltons) are listed to the left of the gels.
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FIGURE 3:
Effect of NP40 Treatment on Extracellular IFITM3 Purified by Ultracentrifugation
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Figure 3. Effect of NP40 Treatment on Extracellular IFITM3 Purified by
Ultracentrifugation. 293β5 cells were transfected with either pCAGGS-hIFITM3
(hIFITM3) or pCAGGS-MCS (Vector). 24 hours post transfection, conditioned media
samples were collected. Cells were lysed with 1% Chaps lysis buffer. Conditioned media
samples were either treated with 0.5% NP40 or no treatment. Exosomes were then
purified from conditioned media samples by ultracentrifugation. ¼ of cell lysates and
purified exosome samples were fractionated on a 4% stacking and 14% resolving gel by
SDS-PAGE. HuIFITM3 and CD81 proteins were detected by Western blotting. Positions
of molecular mass standards (in kilodaltons) are listed to the left of the gels.
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FIGURE 4:
Intracellular and Extracellular IFITM3 Protein Levels in Bronchoalveolar Lavage Fluid
Samples
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Figure 4. Intracellular and Extracellular IFITM3 Protein Levels in Bronchoalveolar
Lavage Fluid Samples. Bronchoalveolar lavage fluid (BALf) samples were obtained
from three patients (identified A-C) at LUMC. Cells were isolated from BALf and lysed
with 0.5% Triton-X lysis buffer. Exosomes were purified from BALf. ¼ of the cell lysate
and ¼ of the exosome sample were fractionated on a 4% stacking aand 14% resolving gel
by SDS-PAGE. Positive controls are indicated “+” and are the cell lysate of HeLa cells
transiently transfected with pCAGGS-HuIFITM3 (lane 1) and exosomes from HeLa cells
transiently transfected with pCAGGS-HuIFITM3 (lane 2). HuIFITM3 proteins were
detected by Western blotting. Positions of molecular mass standards (in kilodaltons) are
listed to the left of the gels.
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FIGURE 5:
Ubiquitination of IFITM3 in Exosomes Purified from Human Bronchoalveolar Lavage
Fluid Samples
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Figure 5. Ubiquitination of IFITM3 in exosomes purified from human
bronchoalveolar lavage fluid samples. (Figures A-C) Bronchoalveolar lavage fluid
(BALf) samples were obtained from several patients at the LUMC bronchoscopy lab
(samples identified as D-G). Exosomes were purified from BALf samples by
ultracentrifugation. ¼ of each exosome sample was fractionated on a 4% stacking and
14% resolving gel by SDS-PAGE. HuIFITM3 and ubiquitin proteins were detected
among each sample by Western blotting. The IFITM3 and ubiquitin band patterns from
the same exosome sample are compared side-by-side. Positions of molecular mass
standards (in kilodaltons) are listed to the left of the gels.
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FIGURE 6:
Effect of IFITM3 cDNA Expression on Exosome Secretion
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Figure 6. Effect of IFITM3 cDNA Expression on Exosome Secretion. 293β5 cells
were transiently transfected with either pCAGGS-HuIFITM3 or pCAGGS-MCS (Vector)
DNA. 24 hours post-transfection, conditioned media were collected. Exosomes were
purified from conditioned media by ultracentrifugation. Cells were lysed with 1% Chaps
lysis buffer. Cell lysates and exosome samples were fractionated by SDS-PAGE.
IFITM3, CD63, and CD81 proteins were detected by Western blotting. Positions of
molecular mass standards (in kilodaltons) are listed to the left of the gels.
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Figure 7:
Percent CD63 and CD81 Secretion Calculated from IFITM3-Expressing Cells
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Figure 7. Effect of IFITM3 cDNA Expression on Exosome Secretion. AlphaView
Software was used to quantitate band densities of CD63 and CD81 Western blots from
Figure 5. Multiplex band analysis tools were used to quantitate pixel density of each
band. Intracellular band densities are pixel densities of the CD63/CD81 signals among
the cell lysates. Exosome band densities are pixel densities of the CD63/CD81 signals
among the exosome samples. BC SUM refers to background corrected pixel density (BC
SUM = Background corrected average * region area). BC SUM ADJUSTED refers to the
BC SUM corrected to represent the entire sample (e.g. ¼ of the exosome samples were
evaluated by Western blot, so BC SUM is multiplied by 4 to represent the entire sample).
Exosome/IntracellularBand Density refers to the BC SUM ADJUSTED for the exosome
sample divided by BC SUM ADJUSTED for the cell lysate.
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FIGURE 8:
Effect of Exosomes on Influenza A Pseudovirus Infection
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Figure 8. Effect of Exosomes on Influenza A Pseudovirus Infection. (A) 293β5 cells
(75% confluent, 15cm dishes) were transiently transfected with either pCAGGSHuIFITM3 or pCAGGS-MCS. 24 hours post-transfection, cell culture supernatants were
obtained. Exosomes were purified from conditioned media by ultracentrifugation.
Exosomes were mixed with various dilutions of Influenza A pseudovirus (hemagglutinin
or HA protein coat-HIV/luciferase core pseudovirus). Exosome-pseudovirus mixtures
were incubated for 1 hour at room temperature. Exosome-pseudovirus mixtures were then
added to 293β5 target cells. 4 hours later, FCS was added to each well for a total of 10%
FCS. 48 hours post-transduction, 293β5 target cells were washed with serum-free media.
Luciferase values (in relative light units) were measured using a luminometer. Each assay
was performed in triplicate. Exosomes from cells transiently transfected with pCAGGSHuIFITM3 are referred to as “HuIFITM3 exosomes.” Similarly, exosomes from cells
transiently transfected with pCAGGS-MCS are referred to as “vector exosomes”. Serumfree media was added to “pseudovirus alone” condition to standardize volumes. (B) ¼
exosome samples were fractionated by SDS-PAGE and subsequently silver stained to
compare total protein levels among the exosome preparations. (C) Cells that were
transiently transfected with pCAGGS-HuIFITM3 and pCAGGS-MCS were lysed with
1% Chaps lysis buffer following collection of the cell culture supernatant. The cell
lysates and exosome samples were fractionated by SDS-PAGE. IFITM3 proteins were
detected by Western blotting. Positions of molecular mass standards (in kilodaltons) are
listed to the left of the gels.
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FIGURE 9:
Effect of Ace2 and HuIFITM3 cDNA Expression on Intracellular and Extracellular Ace2
Protein Levels
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Figure 9. Effect of Ace2 and HuIFITM3 cDNA Expression on Intracellular and
Extracellular Ace2 Protein Levels. HeLa cells were transiently transfected with either
pCAGGS-Ace2-C9, pCAGGS-HuIFITM3, or pCAGGS-MCS. 24 hours posttransfection, conditioned media was collected. Cells were lysed with 1% Chaps lysis
buffers. Exosomes were purified from the conditioned media by ultracentrifugation. 2%
of the total cell lysates and 50% of each exosome sample were fractionated by SDSPAGE. IFITM3 and Ace2 proteins were detected by Western blotting. Positions of
molecular mass standards (in kilodaltons) are listed to the left of the gels.
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FIGURE 10:
Effect of Exosomes on SARS S Pseudovirus Infection
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Figure 10. Effect of Exosomes on SARS Coronavirus Infection. 293β5 cells (75%
confluent, 15cm dishes) were transiently transfected with either pCAGGS-HuIFITM3 or
pCAGGS-MCS. 24 hours post-transfection, conditioned media were obtained. Exosomes
were purified from conditioned media by ultracentrifugation. Exosomes were mixed with
SARS Coronavirus pseudovirus (SARS S coat protein-HIV/luciferase core pseudovirus).
Exosome-pseudovirus mixtures were incubated for 1 hour at room temperature.
Exosome-pseudovirus mixtures were then added to 293β5 target cells. 48 hours posttransduction, 293β5 target cells were washed with serum-free media. Luciferase values
(in relative light units) were measured using a luminometer. Each assay was performed in
triplicate. Exosomes from cells transiently transfected with pCAGGS-HuIFITM3 are
referred to as “HuIFITM3 exosomes.” Likewise, exosomes from cells transiently
transfected with pCAGGS-MCS are referred to as “vector exosomes”. Serum-free media
was added to “pseudovirus alone” conditions to standardize volumes.
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FIGURE 11:
Proposed Model of IFITM3-Mediated Exosome Reduction of Virus Infection Levels
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Figure 11. Proposed Model of IFITM3-Mediated Exosomal Virus Restriction.
IFITM3 and virus receptor proteins are both localized in tetraspanin enriched
microdomains (TEMs) at the plasma membrane. These proteins undergo ubiquitination
and thus endocytosis into the cell. As the endosome acidifies and matures, vesicles bud
inward into the lumen of the endosome. When vesicles bud into the endosome lumen,
various proteins are pulled into the intraluminal vesicles. This structure is now referred to
as a multivesicular body (MVB). One target for MVB’s is the plasma membrane. Upon
fusion of the MVB with the plasma membrane, the intraluminal vesicles will be released
into the extracellular space. These vesicles are now referred to as exosomes. The virus
receptor proteins on exosomes can bind to virus in the extracellular space, thereby
preventing the virus from going on to infect the host cell.
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